乐观
$89.49
情景价格
$94.230
+1.234 (+1.31%)收盘时
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
Medtronic PLC appears to be a good buy at the current price of $88.48, especially given its strong fundamentals and positive catalysts. The company raised its dividend for the 49th consecutive year, indicating a commitment to shareholder returns, and analysts project a revenue growth of 7.25%-7.75% for fiscal 2027. However, the stock has faced challenges, reflected in a 7.88% year-to-date decline. The forward P/E ratio is attractive at 14.93, suggesting potential for upside.
BTIG
$99
2026-10-12
BTIG
2026-10-12
目标价
$99
Barclays
$95
2026-10-06
Barclays
2026-10-06
目标价
$95
Deutsche Bank
$92
2026-09-03
Deutsche Bank
2026-09-03
目标价
$92
UBS
$110
2026-09-03
UBS
2026-09-03
目标价
$110
Mizuho
$115
2026-09-02
Mizuho
2026-09-02
目标价
$115
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Boeing Board Restructuring Boosts Confidence

Investment Insights: Focus on McKesson and Medtronic

Medtronic Completes MiniMed Share Exchange

Intensifying Competition in Pharma Sector: Investor Focus Required

Medtronic's Share Exchange Offer Oversubscribed
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
Medtronic PLC appears to be a good buy at the current price of $88.48, especially given its strong fundamentals and positive catalysts. The company raised its dividend for the 49th consecutive year, indicating a commitment to shareholder returns, and analysts project a revenue growth of 7.25%-7.75% for fiscal 2027. However, the stock has faced challenges, reflected in a 7.88% year-to-date decline. The forward P/E ratio is attractive at 14.93, suggesting potential for upside.
23 analysts cover MDT: 11 rate it Buy, 12 Hold and 0 Sell. The average price target is 111.76.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。